RAYDIAX GmbH – RAYDIAX TACT

The Problem

Interventional Oncology is emerging as the fourth pillar of cancer care, offering clear advantages over traditional surgery, including fewer complications, shorter procedures, and reduced hospitalization. However, imaging systems used today were originally designed for diagnostics – not for guiding complex cancer interventions in real time.

This results in limitations in tumor targeting precision, radiation exposure, workflow efficiency, and complication management. There is currently no imaging system on the market specifically built to meet the demands of modern interventional oncology.

The Project

Raydiax has developed TACT (Therapy Assistance Computed Tomograph), the first imaging system tailored specifically to interventional oncology.

TACT combines CT and angiography in a compact 2-in-1 hybrid system and integrates proprietary hardware and software innovations. Its patented spotlight technology enables up to 40% radiation dose reduction, while dedicated interventional workflow software and image-based needle tracking significantly improve precision, usability, and safety.

By transforming imaging from a diagnostic tool into an integrated therapeutic platform, TACT enables more precise, efficient, and accessible cancer interventions.

The Impact

With strategic support from Evolution Europe, Raydiax secured EIC Accelerator blended finance to complete clinical validation, obtain CE and FDA approval, and prepare for commercialization.

TACT enables hospitals to reduce intervention costs, increase treatable patient numbers, and significantly lower space requirements. By making advanced interventional oncology accessible beyond highly specialized centers, Raydiax contributes to expanding high-quality cancer care to a broader patient population.

The Result

As a result of this successful EIC Accelerator application, Raydiax secured blended finance to accelerate regulatory approval, validation, and market entry of TACT, consisting of a €2.5 million grant and €6 million in equity investment, a total of approximately €8.5 million of European public-private funding.

This milestone positions the company to set a new global standard in imaging for interventional oncology and to drive the next generation of precision cancer treatment.